CD7 expression

These data position polyclonal small- and large-plaque dermatitis lesions as a separate disease entity, that characteristically harbors a so far undescribed ILC population. We thus propose the new term "polyclonal parapsoriasis en plaque" to this kind of lesions, as they can be clearly differentiated from early and advanced-stage MF, psoriasis and AD on several cellular and molecular levels.

T cells regenerating after lymphodepletion lacked CD7 expression, were polyclonal and responded to SARS-CoV-2 vaccination; CD7+ immune cells reemerged concomitantly with CAR T cell disappearance. In conclusion, autologous anti-CD7 PEBL-CAR T cells have powerful antileukemic activity and are potentially an effective option for the treatment of T-ALL.

Overall survival was inferior (11.9 [95% CI, 9.7-15.9] vs. 19.0 months [95% CI, 16.1-23.0], p = 0.0174). At relapse, 30.4% lost and 19.0% gained CD7, suggesting moderate instability over time.

Furthermore, multivariate analysis showed that CD7+ with DNMT3A mutation was an independent risk factor for OS and RFS. CD7+ with DNMT3A mutation predicts a poor prognosis in AML patients, and the immunophenotype combined with molecular genetic markers can help to further refine the current risk stratification of AML.

This study showed that RAD21-mutated AML often associates with monocytic differentiation, CD7 expression, co-existing mutations in epigenetic regulators, a normal karyotype, and poor prognosis. Our findings provide additional insights into the morphologic, immunophenotypic, and genomic profile of RAD21 mutation-positive AML and suggest that RAD21 mutations should be evaluated for independent prognostic significance in AML.

Treatment with an eight-week course of etoposide and dexamethasone for HLH led to rapid clinical improvement. Although potentially fatal, FUMHD often exhibits favorable outcomes and may resolve without recurrence, as in our patient. FUMHD should be considered in the differential diagnosis for patients presenting with cutaneous CD8+ necrotizing angiocentric lymphoproliferative disease complicated by HLH.

P1/2, N=26, Not yet recruiting, Bambino Gesù Hospital and Research Institute | Trial completion date: Feb 2040 --> Jun 2040 | Initiation date: Oct 2023 --> Jan 2024 | Trial primary completion date: Mar 2028 --> Jun 2028

For first-line treatment, in addition to frequent steroid use, 16 pts (70%) received a methotrexate-based regimen, 6 (26%) received a cyclophosphamide-based regimen, and 1 (4%) received a cyclosporine-based regimen. In this large cohort of 45 pts, the majority had neutropenia and anemia, and approximately half required systemic treatment. Estimated median OS from diagnosis exceeded a decade for the entire cohort and was seven years after treatment initiation. Anemia was associated with a shorter TTFT, while increasing age and lack of CD94 expression were associated with worse OS.

This product could be delivered alone or in combination with additional CARs for dual targeting, such as anti-CD5 or anti-CD7 CARs, to reduce the potential of antigen-negative escape. Further research is ongoing to study the effect of CD2 deletion in anti-CD19 CAR T cells and the possible implication for clinical translation.

A lymphodepletion regimen was administered to all patients using fludarabine (30 mg/m2 per day) and cyclophosphamide (500 mg/m2 per day) for three consecutive days (day -5 to day -3) before CAR-T infusion. UCD7-CAR T therapy is a safe and highly effective pediatric T-ALL/LBL treatment. More patients and longer follow-ups are needed for validation.

All patients received intravenous fludarabine (30mg/m2/d) and cyclophosphamide (300mg/m2/d) lymphodepletion chemotherapy for three consecutive days (Day -5 to Day -3). The safety profile of NS7CAR-T therapy was manageable. However, to comprehensively assess the efficacy of NS7CAR-T in treating CD7-positive AML, further data from a larger cohort of patients and longer follow-up time are essential.

P1, N=54, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting

P1/2, N=26, Not yet recruiting, Bambino Gesù Hospital and Research Institute

This case report highlights an unusual pathological manifestation this lymphoma. Poster type: Poster Defense

In MDS, the expression of lymphoid-associated antigens on maturing and mature myelomonocytic cells is a rare anomaly, with CD4 expression typically observed only in eosinophils among normal human granulocytes. However, our small cohort of MDS patients observed CD4 expression on neutrophils. We believe that CD4 expression on neutrophils could be a marker for evaluating dysplasia and may be associated with poor prognosis.

CASE PRESENTATION: A 92-year-old male with a history of large granular lymphocytic leukemia complicated by anemia requiring chronic transfusions, previously treated with low dose methotrexate with decrease in transfusion burden, presented with shortness of breath and hypoxemia requiring 15LPM supplemental oxygen via non-breather facemask... T-cell LGL leukemia can have multiple thoracic manifestations including pleural and pulmonary parenchymal and vascular involvement. Metastatic disease should always be considered along with infection when assessing a patient with thoracic disease who has T-cell LGL leukemia.

We propose that the presence of co-occurring ASXL1, SRSF2, and SETBP1 mutations can be diagnostic of a subtype of MDS/MPN with neutrophilia if clinical and morphological findings align. Our report underscores the association between genotype and phenotype within MDS/MPN and that genomic signatures should guide categorization of these entities.

Interestingly, levels of CD4+7– and CD26– are similar in B1 involvement, despite the ISCL criteria defining B2 involvement as a lower relative loss of CD26–. Identifying B1 patients is important as certain therapeutic options such as extracorporeal photopheresis and mogamulizumab may be indicated in patients with early-stage MF, refractory to skin-directed therapies.

P1, N=48, Not yet recruiting, Washington University School of Medicine | Trial completion date: Sep 2025 --> Jan 2026 | Initiation date: Mar 2023 --> Jul 2023 | Trial primary completion date: Sep 2025 --> Jan 2026

These findings indicate P2RY8-CRLF2 identifies a subset of patients with specific features and adverse outcomes that could be improved by risk-directed treatment.

It is promising to select appropriate AML patients for CD7-CAR-T therapy according to analyze the CD7 expression on tumor cells.

In this 2-year follow-up analysis, donor-derived CD7 CAR T-cell treatment demonstrated durable efficacy in a subset of patients with r/r T-ALL. Disease relapse was the main cause of treatment failure, and severe infection was a noteworthy late-onset adverse event.

P=N/A, N=100, Active, not recruiting, Hebei Senlang Biotechnology Inc., Ltd. | Recruiting --> Active, not recruiting

It also exhibited efficacy in inhibiting xenograft tumor growth in vivo. More exploration is needed for clinical efficacy potential to CD7 positive patients.

P1, N=48, Not yet recruiting, Washington University School of Medicine | Trial completion date: Jun 2025 --> Sep 2025 | Initiation date: Dec 2022 --> Mar 2023 | Trial primary completion date: Jun 2025 --> Sep 2025

Naturally selected CD7 CAR-T cells represent an effective treatment strategy for relapsed and refractory acute myeloid leukaemia patients in preclinical studies.

P=N/A, N=100, Recruiting, Hebei Senlang Biotechnology Inc., Ltd.

Only one patient had a grade 3 CRS and a serious grade 4 ICANS, resolved by dexamethasone and tocilizumab. The major challenge on prevent post-treatment infection may be the protection from loss of monocytes. Key words CD7 CAR-T immunotherapy; Immune Reconstitution; Single-cell Transcriptomic Analysis; T-ALL

Among the 55 patients, the median age at time of CML-BP diagnosis was 45 years (17 - 68) and included 35 (64%) cases of CML in myeloid BP (MBP) and 20 (36%) cases of lymphoid BP (LBP). 40 (72%) patients had transformed from a previous CP/AP with a median time of 2.4 years (0.1 – 19.3) from initial diagnosis to transformation. Extramedullary disease was present in 18/53 (34%) patients.

All patients received intravenous fludarabine (30 mg/m2/d) and cyclophosphamide (300 mg/m2/d) (FC) for 3 days before NS7CAR infusion. Patients with STIL-TAL1 tend to have a poorer response and early relapse. When relapse occurs, loss of CD7 expression was observed.

Before the CAR T-cell therapy, the patient achieved partial remission with IA regimen and attained complete remission after reinduction therapy (decitabine and venentoclax)...Then she failed CLIA regimen combined with venetoclax and exhibited resistance to FLT3 inhibitors...In summary, the autologous CD7 CAR T-cell therapy could be considered a potential approach for AML with CD7 expression (NCT04762485).Trial registration Clinical Trials.gov, NCT04762485. Registered on February 21, 2021, prospectively registered.

P1, N=48, Not yet recruiting, Washington University School of Medicine | Trial completion date: Feb 2025 --> Jun 2025 | Initiation date: Aug 2022 --> Dec 2022 | Trial primary completion date: Feb 2025 --> Jun 2025

He has remained free from clinical recurrence for 4 months since the initial biopsy. To our knowledge, this represents the 15th reported case of LyP with DUSP22-IRF4 rearrangement, adding to the growing pool of documented cases featuring this novel entity.

He has remained free from clinical recurrence for 4 months since the initial biopsy. To our knowledge, this represents the 15th reported case of LyP with DUSP22-IRF4 rearrangement, adding to the growing pool of documented cases featuring this novel entity.

ATLL is associated with human T lymphotropic virus (HTLV-1) infection, usually in endemic areas such as Japan and Caribbean countries. CD4+/CD7- is the most common immunophenotypic findings of ATLL. ATLL can rarely show unu-sual immunophenotypes and frequently accompanied by complex cytogenetics/NGS findings.

The histologic diagnosis of MF especially at early stage is one of the most vexing problems in dermatopathology, because the histopathologic features may simulate a variety of inflammatory skin disorders. Immunohistochemistry can help in diagnosis in some cases. Hower, clinicopathological correlation remains the "gold standard" for making an accurate diagnosis.

T-cell receptor gene rearrangement studies performed on biopsy sections were positive in all biopsies (n = 6), whereas peripheral blood T-cell receptor gene rearrangement studies did not identify clonality. In conclusion, GMF has subtle or absent epidermotropism and variable granulomatous reaction; thus, the diagnosis requires a multimodal approach, and our proposed algorithm provides a framework to approach this diagnostic challenge.

P1, N=48, Not yet recruiting, Washington University School of Medicine